摘要
目的探讨小儿生血糖浆联合蛋白琥珀酸铁治疗小儿缺铁性贫血的临床疗效。方法选取2019年1月—2019年12月郑州大学第一附属医院收治的小儿缺铁性贫血患儿264例,随机分为对照组和治疗组,每组各132例。对照组口服蛋白琥珀酸铁口服溶液,1.5 mL/kg,2次/d。治疗组在对照组基础上口服小儿生血糖浆,10 mL/次,2次/d。两组患儿持续治疗1个月。观察两组患者临床疗效,同时比较治疗前后两组患儿血常规,平均红细胞蛋白量(MCH)、红细胞体积(MCV)和红细胞分布宽度(RDW)水平,铁代谢指标及生活质量(QOL)评分。结果治疗后,治疗组临床总有效率为94.70%,显著高于对照组的79.55%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患儿的血红蛋白和血清铁蛋白水平明显高于治疗前(P<0.05),治疗组患儿血红蛋白和血清铁蛋白水平明显高于对照组(P<0.05)。治疗后,两组患儿MCH和MCV水平明显高于治疗前(P<0.05),而RDW水平明显低于治疗前(P<0.05);且治疗组治疗后的MCH、MCV和RDW水平显著好于对照组(P<0.05)。治疗后,两组患儿血清铁(SI)水平明显高于治疗前(P<0.05),而总铁结合力(TRBF)和血清转铁蛋白(TF)水平明显低于治疗前(P<0.05),治疗组SI、TRBF和TF水平显著好于对照组(P<0.05)。治疗后,两组患儿QOL评分明显高于治疗前(P<0.05),且治疗组显著高于对照组(P<0.05)。结论小儿生血糖浆联合蛋白琥珀酸铁口服溶液治疗小儿缺铁性贫血的整体疗效显著,可有效改善贫血以及铁代谢指标,提高患儿生活质量。
Objective To explore the clinical study of Xiaoer Shengxue Syrup combined with Iron Proteinsuccinylate Oral Solution in treatment of iron deficiency anemia in children.Methods Children(264 cases)with iron deficiency anemia in the First Affiliated Hospital of Zhengzhou University from January 2019 to December 2019 were randomly divided into control and treatment groups,and each group had 132 cases.Children in the control group were po administered with Iron Proteinsuccinylate Oral Solution,1.5 mL/kg,twice daily.Children in the treatment group were po administered with Xiaoer Shengxue Syrup on the basis of the control group,10 mL/time,twice daily.Children in two groups were treated for 1 month.After treatment,the clinical efficacy was evaluated,and the routine blood test,the MCH,MCV,and RDW levels,the iron metabolism indexes and QOL scores in two groups before and after treatment were compared.Results After treatment,the clinical efficacy in the control group was 79.55%,which was significantly lower than 94.70%in the treatment group,and there were differences between two groups(P<0.05).After treatment,hemoglobin and serum ferritin in two groups were significantly increased(P<0.05),and which in the treatment group were significantly higher than those in the control group(P<0.05).After treatment,the MCH and MCV levels in two groups were significantly increased(P<0.05),but the RDW levels in two groups were significantly decreased(P<0.05),and the indexes in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the SI levels in two groups were significantly increased(P<0.05),but the TRBF and TF levels in two groups were significantly decreased(P<0.05),and the levels of SI,TRBF and TF in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the QOL scores in two groups were significantly increased(P<0.05),and which in the treatment group were significantly higher than that in the control group(P<0.05).Conclusion The overall ef
作者
向明丽
王颖超
麻彦
李艺
尼晓丽
XIANG Ming-li;WANG Ying-chao;MA Yan;LI Yi;NI Xiao-li(Department of Pediatric Hematology Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《现代药物与临床》
CAS
2020年第11期2163-2167,共5页
Drugs & Clinic
基金
河南省科技厅社发攻关项目(172102310079)。
